Compare Capital One Financial Corp. (COF) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Merck & Co., Inc. — how do they compare? Capital One Financial Corp. trades at $218.09 (market cap $134.45B), while Merck & Co., Inc. trades at $129.69 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 2.4× Capital One Financial Corp.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| COF | MRK | |
|---|---|---|
Market Cap | $134.45B | $321.77B |
Sector | Financials | Health |
52-Week High | $257.94 | $131.84 |
52-Week Low | $176.10 | $77.60 |
Dividend Yield | 1.46% | 2.61% |
Enterprise Value | — | $368.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $218.97, up 0.56% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81, while revenue growth accelerated to $53.43B in 2025. The Discover integration is on track, targeting $2.5B in synergies by late 2027, supporting double-digit EPS growth projections.
The outlook is positive, driven by strong card growth, technology advantages, and merger synergies, but risks include integration execution, credit loss provisions, and macroeconomic sensitivity. With a P/E of 12.07 and 63% analyst buy ratings, the stock offers value if Discover benefits materialize as planned.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
